Tag Archives: NASDAQ:ADVM

Chardan Capital Sticks to Their Hold Rating for Adverum Biotechnologies (ADVM)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Hold rating on Adverum Biotechnologies (NASDAQ: ADVM), with a price target of $4.50. The company’s shares closed yesterday at $4.55. Amusa said: “We had previously expressed concerns on

Chardan Capital Keeps Their Hold Rating on Adverum Biotechnologies (ADVM)

In a report released today, Gbola Amusa from Chardan Capital reiterated a Hold rating on Adverum Biotechnologies (NASDAQ: ADVM), with a price target of $8. The company’s shares closed yesterday at $4.75. According to TipRanks.com, Amusa is a 5-star analyst

Adverum Biotechnologies Gets a Hold Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa assigned a Hold rating to Adverum Biotechnologies (NASDAQ: ADVM) today. The company’s shares opened today at $3.25. Amusa said: “We note PRVs have in 2017 sold for: 1) $130 mm to Ultragenyx Pharmaceutical (unrated), announced

Chardan Capital Reaffirms Their Hold Rating on Adverum Biotechnologies

Chardan Capital analyst Gbola Amusa maintained a Hold rating on Adverum Biotechnologies (NASDAQ: ADVM) today and set a price target of $3.50. The company’s shares closed on Friday at $2.80. According to TipRanks.com, Amusa is a 1-star analyst with an

Cowen & Co. Thinks Adverum Biotechnologies’ Stock is Going to Recover

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Adverum Biotechnologies (NASDAQ: ADVM) yesterday. The company’s shares closed yesterday at $2.75, close to its 52-week low of $2.50. Nadeau said: “ADVM ended Q1 with $210MM in cash.” According